Thermo Fisher Scientific Inc. said it is buying Brammer Bio for $1.7 billion in a move that would expand the lab-equipment company’s presence in the rapidly growing field of gene therapy. Closely held Brammer Bio, owned by private-equity firm Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drugmaking services. Gene...
Pharmaceutical research equipment manufacturer Thermo Fisher has expanded in the gene therapy space with its $1bn acquisition of viral vector maker Brammer Bio from Ampersand Capital Partners. Thermo CEO Marc Casper said official takeover talks began earlier this year and the two firms were already collaborating on some services. Thermo anticipates Brammer's 2019 total revenue will be $250m. The gene therapy contract development and manufacturing market is currently worth $1.7bn and is growing at more than 25% annually, Casper added.